Drugmaker Granules India’s U.S. subsidiary Granules Pharmaceuticals, Inc. (GPI) has accomplished U.S. Food and Drug Administration’s post-marketing hostile drug expertise (PADE) inspection for all its entities within the U.S.
The inspection, carried out from July 31-August 3, and closed with zero observations, coated Granules’ PADE surveillance, receipts, evaluations, processing and reporting system for the marketed drug merchandise worldwide. This was Granules India’s fourth FDA audit since March with zero observations, the corporate stated on Friday.
